Impact of Rituximab (RTx) Induction and Living Donation on Immunoregulation and Virus Control in Renal Transplantation
Impact of Rituximab Induction and Living Donation on Immunoregulation and Virus Control in Renal Transplantation - a Prospective Pilot Study
Sponsor: Astellas Pharma US, Inc.
A PHASE2 clinical study on Immunology and Kidney Transplantation, this trial is completed. The trial is conducted by Astellas Pharma US, Inc. and has accumulated 8 data snapshots since 2010. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Nov 2019 — Jan 2021 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jun 2019 — Nov 2019 [monthly]
Active Not Recruiting PHASE2
▶ Show 3 earlier versions
-
Jun 2018 — Jun 2019 [monthly]
Active Not Recruiting PHASE2
-
Dec 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Dec 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Jan 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Astellas Pharma US, Inc.
- German Cancer Research Center
- Heidelberg University
- Novartis
- University of Giessen
For direct contact, visit the study record on ClinicalTrials.gov .